On May 19, 2016 Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, reported that the Company was selected for a poster presentation at the 2016 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held from June 3 – 7 in Chicago, IL (Press release, Bellicum Pharmaceuticals, MAY 19, 2016, View Source;p=RssLanding&cat=news&id=2169692 [SID:1234512568]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Also in June, data from the ongoing BP-004 clinical trial of BPX-501, the Company’s adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation, will be discussed by Dr. Alice Bertaina, Head of Stem Cell Transplant at Ospedale Pediatrico Bambino Gesù in an oral presentation at the 21st Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) being held from June 9 – 12 in Copenhagen, Denmark.

ASCO Presentation Details:

Presentation Title: "Enhanced efficacy and safety of Her2-targeted chimeric antigen receptor (CAR) T cells using MyD88/CD40 costimulation and iCaspase-9 suicide switch"
Abstract Number: 3050
Poster Board: #372
Session Name: Developmental Therapeutics – Immunotherapy
Date: Sunday, June 5, 2016
Presentation Time: 8:00 AM – 11:30 AM CDT (9:00 AM – 12:30 PM EDT)

EHA Oral Presentation Details:

Presentation Title: "Infusion of BPX-501 (donor T cells transduced with the iC9 suicide gene) after α/β T-cell depleted haplo-HSCT in children with acute leukemia: Preliminary results of a Phase I-II trial"
Abstract Number: S523
Session Name: Stem cell transplantation – Clinical 1
Date: Saturday, June 11, 2016
Presentation Time: 4:30 PM – 4:45 PM CEST (10:30 AM – 10:45 AM EDT)